AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06771089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and bandaging
Description: The MTG group received an intervention based on anterior-posterior mobilizations of the talus and fibula and taping, both based on Mulligan® techniques Individually, participants received Grade IV passive mobilizations lasting approximately 30 seconds, totalling 12 active mobilizations performed by the participant. Furthermore, a tape was applied, placed on the anterior part of the talus with a posterior and caudal direction, with its ends anchored near the heel. Due to its placement, this taping maintained a sustained posterior force on the talus throughout the training session. This intervention was conducted on the affected limb(s) with DF deficits.
Study NCT06771089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise protocol lasting approximately 5-10 minutes, performed before regular training sessions. It included 2 exercises, each performed in 3 sets of 10 repetitions with 1-minute rest intervals.~Exercise 1: Weighted DF in a kneeling position. From this position, ankle DF is performed with the front leg, on which the weight of the arms and the torso is placed to force the movement.~Exercise 2: Ankle lunge with band resistance at the ankle. The player performs ankle DF with a medium-resistance green Theraband® providing a posterior force vector on the talus.~This intervention was applied to the affected limb(s) with ankle DF limitations and was supervised by a physiotherapist. It was performed before training session at each club's facilities.
Study NCT06771089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No specific treatment
Description: The Control group received no specific treatment; they only participated in the current training sessions.
Study NCT06770296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib low dose group
Description: Pyrotinib: 320mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study NCT06770296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib normal dose group
Description: Pyrotinib: 400mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study NCT06771024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention include a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. International/national exercise prescription guidelines will be applied for each clinical condition (cardio/cerebrovascular disease/risk, diabetes mellitus and osteoarthritis).
Study NCT06771596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab Injection
Description: Nimotuzumab is a highly humanized monoclonal antibody of IgG1 type, with a humanization rate of 95%. It is highly specific, has a long half - life, and shows high selectivity and a high degree of humanization. It can specifically block the epidermal growth factor receptor (EGFR) signaling pathway and mediate immune effects such as antibody - dependent cell - mediated cytotoxicity (ADCC) and complement - dependent cytotoxicity (CDC). It also promotes the endocytosis and degradation of EGFR, thereby inhibiting the proliferation of tumor cells and promoting the apoptosis of tumor cells, reversing the malignant biological behavior of tumor cells at the molecular level.
Study NCT06771492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic treatment (amoxicillin) with a dosage of 1000 mg (3 times a day) for a period of 100 days
Study NCT06771492 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with a dose of 1000 mg (3 times a day) for a period of 100 days
Study NCT06771999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention by a clinical pharmacist
Description: All participants will respond to two questionnaires, both validated in Romanian and some demographic information. One is the rPATD questionnaire that investigate attitudes towards deprescribing of medication and the other one is the HLS-EU-Q16 that investigates medical literacy of participants. After completion, the clinical pharmacist will give a brochure and a video about the process of deprescribing, information about the efficacy and the adverse reactions of medicines and the role of pacient in treatment decision. When participants come to another cancer treatment (after 14 , 21 or 28 days), the rPATD will be completed again.
Study NCT06505759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelain gel
Description: bromelain gel is prepared from bromelain capsules in laboratory
Study NCT06505759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gel
Description: chlorhexidine gel is prepared from mouth wash
Study NCT06505759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: Scaling and root planing was done with ultra sonic and hand scaling
Study NCT04294043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Description: Study subjects will receive an infusion of gallium nitrate.
Study NCT04652700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: ISL 60 mg tablet, QM, orally for up to 24 months
Study NCT04652700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
Study NCT04652700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TAF
Description: Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
Study NCT04652700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ISL
Description: Placebo ISL 0 mg tablets QM, orally for up to 24 months.
Study NCT04652700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to FTC/TDF
Description: Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
Study NCT04652700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to FTC/TAF
Description: Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
Study NCT05949840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive Interviewing
Description: Automated computer system designed to engage participants in discussion about challenges faced during the COVID-19 pandemic.
Study NCT06072638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating in Absence of Hunger
Description: Researcher gives child free access to palatable foods following a satiating meal.
Study NCT05725941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TogRite stretch Strapping
Description: it is a machine washable and highly durable elastic strap that maintains its recoil strength for a long-lasting period. It is made of latex-free materials. The TogRite Strapping can be used to support the weakened parts of the body and adjust or modify the position and posture of different body parts.
Study NCT05725941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional upper limb functional exercise training
Description: The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.
Study NCT05725941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional upper limb functional exercise training
Description: The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.
Study NCT05223868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.
Study NCT05223868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study NCT06366243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablet
Study NCT06366243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral delayed-release capsule
Study NCT05023031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-2102
Description: Tablet formulation for oral administration, single dose of NVP-2102 at Day 1
Study NCT05023031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2102-R
Description: Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1
Study NCT05071924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH Teens Original: In-person PLH programme for parents and teens by community-based workers
Description: This in-person intervention is delivered over 14 sessions (10 joint parent and teen sessions and 4 separate parent and teen sessions).
Study NCT05071924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH Teens Hybrid: Hybrid delivery for parents and teens by facilitators
Description: The hybrid intervention delivered over 12 sessions (8 sessions delivered via WhatsApp groups to parents only and 4 sessions delivered in-person to parents and teens together).
Study NCT04869241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: surface EMG
Description: Carrying backpacks forward or backward
Study NCT04764552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeahhh Baby Ointment
Description: The ointment consists primarily of coconut oil (98%), with small amounts of herbal ingredients (tanner's bark, slippery root, sweet weed, velvet plant, walnut hulls, kidney root, green ginger, Indian pink, mad dogweed, and nigella seed) thought to reduce inflammation and to promote tissue healing.
Study NCT04764552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coconut oil ointment
Description: Coconut oil ointment with a little olive oil.
Study NCT05223868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study NCT05647369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mastic mouthwash
Description: All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
Study NCT05647369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
Study NCT06298149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turtle Island Tales
Description: All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
Study NCT04321551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cyp 200Mg/Ml Inj (in Oil)
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
Study NCT04321551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
Study NCT05112510 — intervention group
Intervention type: OTHER
Intervention: Observing whether developing distant metastasis or recurrence
Description: The study is a observational study and has no intervention.
Study NCT05956041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400mg Intravenously
Study NCT05956041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: 1mg/kg Intravenously
Study NCT06431750 — intervention group
Intervention type: OTHER
Intervention: Secukinumab
Description: This is an observational study, there is no treatment allocation.
Study NCT06418867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness Practice including 6 sessions with 1 hour for each
Study NCT05984433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Electro auricular acupuncture
Study NCT04735640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led teleconsultation
Description: Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.
Study NCT04735640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
Study NCT05398198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 dose and administration as per study intervention.
Study NCT05398198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3923868 will be administered.
Study NCT06307704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound - guided Stepwise PEEP
Description: After endo-tracheal intubation; A PEEP of 4 cmH2O will be initially used till 5 min after pneumoperitoneum. Then The PEEP will be adjusted in a stepwise approach after performing bedside lung ultrasound. The PEEP will be increased by 2 cmH2O until no lung collapse is detected. Lung ultrasound will be repeated 5 min after every change in the PEEP with a maximal PEEP of 12 cmH2O.
Study NCT06307704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ventilation Protocol
Description: Volume-controlled ventilation (VCV) mode; with a tidal volume of 6 mL/kg of ideal weight, inspiratory : expiratory ratio 1: 2, PEEP 4 cmH2O, respiratory rate adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mm Hg, and inspired oxygen fraction of 50%.
Study NCT06307704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Ventilation Protocol
Description: Volume-controlled ventilation (VCV) mode; with a tidal volume of 6 mL/kg of ideal weight, inspiratory : expiratory ratio 1: 2, PEEP 4 cmH2O, respiratory rate adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mm Hg, and inspired oxygen fraction of 50%.
Study NCT04920773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guduchi Ghanvati
Description: 500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
Study NCT05184829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selective lymph node dissection
Description: selective lymph node dissection
Study NCT05085145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus vaccine
Description: Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
Study NCT06098833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Study NCT06098833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-Blend
Description: Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Study NCT06480630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
Study NCT05073471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patterned Sensory Enhancement (PSE)
Description: Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily.
Study NCT05073471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure.
Study NCT05234671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: 12-week exercise programme. The estimated session's duration of 55 minutes. For the prescription of high intensity interval training (HIIT) and the collection of individualised peak power output (PPO) a baseline peak oxygen uptake on an arm crank ergometer will be performed. Each session will consist of 5 minutes warm up performing light to moderate intensity arm cranking (55-65% PPO), 30-minutes' high intensity interval training (HIIT; 30s 100% PPO/ 30s passive recovery) on an arm crank ergometer. The HIIT protocol will be combined with resistance training (RT) lasting for a total of 15 min.The intensity will be at 75-80% of one repetition maximum. Following each exercise session, patients will undertake a 5 min cool-down period.
Study NCT06251947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim Alfa
Description: Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Study NCT04503005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time Restricted Eating
Description: Effect of 16, 14 or 12 hours of daily fasting
Study NCT04503005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time Restricted Eating
Description: Effect of 16, 14 or 12 hours of daily fasting
Study NCT04920773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard guidelines
Description: Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
Study NCT05013801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic facial serum Q69
Description: Cosmetic facial serum
Study NCT05013801 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 2% Hydroquinone
Description: 2% Hydroquinone cream
Study NCT06493162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Patients will be intubated with 5mm sized endotracheal tube for microscopic laryngeal surgery
Study NCT06493162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow Controlled Ventilation
Description: Patients in FCV group will be ventilated with flow controlled ventilation mode